VRS
RVNC

Virginia Retirement Systems’s Revance Therapeutics, Inc. RVNC Stock Holding History

Virginia Retirement Systems’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-13,700
Closed -$347K – 1053
2023
Q2 		$347K Sell
13,700
-300
-2% -$9.35K ﹤0.01% 809
2023
Q1 		$451K Buy
14,000
+900
+7% +$28.1K ﹤0.01% 770
2022
Q4 		$242K Buy
+13,100
New +$300K ﹤0.01% 1015
2022
Q1 		$433K Buy
+22,200
New +$337K ﹤0.01% 887

Other funds holding RVNC

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Virginia Retirement Systems's RVNC Position: Q3 2023 in Review

Virginia Retirement Systems sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2023, closing a stake of 13,700 shares — an estimated $347K sold.

Virginia Retirement Systems first reported a position in RVNC in Q1 2022 and held it in 4 quarters. The position peaked at $451K in Q1 2023. 186 funds tracked by Wall St. Rank hold RVNC as of Q3 2023.

  • Virginia Retirement Systems reported no remaining Revance Therapeutics, Inc. position as of Q3 2023 after selling out during the quarter.
  • Virginia Retirement Systems sold 13,700 Revance Therapeutics, Inc. shares in Q3 2023, an estimated $347K.
  • Virginia Retirement Systems first reported a position in Revance Therapeutics, Inc. in Q1 2022 and held it in 4 quarters.
  • Virginia Retirement Systems's Revance Therapeutics, Inc. position peaked at $451K in Q1 2023.
  • 186 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2023.

Based on Virginia Retirement Systems's 13F filing for Q3 2023, filed 2 Jan 2024.